Shots:
- BI has entered into a strategic research collaboration with Combotope to leverage its SMART-Phage platform to produce highly tumor-selective antibodies for next-generation cancer therapies
- Combotope will discover tumor-selective, high-affinity antibodies against multiple BI oncology targets, while BI will hold global development & commercialization rights, and lead further R&D, manufacturing, & commercialization activities
- As per the deal, Combotope will receive an upfront payment & research funding per target, plus development, regulatory, & commercial milestone payments across multiple targets, with royalties on net sales of any resulting products; financial details remain undisclosed
Ref: PRnewswire | Image: BI & Combotope | Press Release
Related News: Boehringer Ingelheim Inks ~$ 479.6M Deal with Immunitas Therapeutics for a Preclinical Antibody Program
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
